Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Inclusion Criteria

• •Participant must be healthy in the Investigator's clinical judgment on the basis of medical history, physical examination and vital signs performed at Screening
• •Participant must be healthy on the basis of clinical laboratory tests and electrocardiogram (ECG) (only in participants \>50 years) performed at Screening. If the results of the laboratory screening tests and ECG are outside the institutional normal reference ranges, the participant may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study
• •A woman of childbearing potential must have a negative urine β-human chorionic gonadotropin \[beta-hCG\] pregnancy test at Screening and a negative urine \[beta-hCG\] pregnancy test immediately prior to each study vaccine administration
• •A man who is sexually active with a woman of childbearing potential must be willing to use condoms for sexual intercourse beginning prior to dose 1 vaccination until at least 3 months after the dose 2 vaccination, unless a vasectomy was performed more than 1 year prior to Screening
• •Participant must pass the test of understanding (TOU)